You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest General Articles
Popular General Articles
Highly Recommended General Articles
Send a link to this page to your friends and colleagues.
Novo Nordisk Pharmaceuticals of Denmark violated federal regulations for inaccurately representing the type 2 drug Prandin (repaglinide) in promotional materials, according to the U.S. Food and Drug Administration (FDA).
In a May 1 statement, the FDA announced that the drug manufacturer understated the risks of Prandin and inflated its efficacy in advertising paraphernalia such as posters, sales aids and professional exhibits.
The FDA asked that Novo Nordisk immediately discontinue those materials and any others making such claims.
In an interview with Reuters Health, Novo Nordisk spokeswoman Susan Jackson denied that the company violated FDA regulations.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.